Last checked at 
Allergy Therapeutics PLC - Sussex, England-based biotechnology company - Treats its first patient in the third phase of its paediatric trial of Grass Mata MPL. The trial aims to evaluate the long-term efficacy and safety of the drug in treating children with grass pollen allergies. The drug was trialled in adults last year, and showed a "highly statistically significant reduction in the combined symptom and medication score". Grass Mata MPL addresses the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, and works to modify the body's allergic response in as few as six injections ahead of the allergy season.
Chief Executive Officer Manuel Llobet says: "Building on our successful adult trials, this study will help us understand how our short-course immunotherapy can benefit children affected by grass allergies, potentially transforming their treatment journey."
Current stock price: 5.30 pence
12-month change: up from 1.80p
By Lydia Doye, Alliance News news reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
